RaySearch Laboratories ABRSLBF +0.81%92 Days Payable is 121.14 as of Mar. 2026, which is 23% below its 10-year median of 156.86. GuruFocus rates RSLBF with a GF Score™ of 92/100 and a GF Value™ of $20.80 (Fairly Valued). The stock has 2 warning signs investors should review. Among 607 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 72.98% on this metric.
The historical rank and industry rank for RaySearch Laboratories AB's Days Payable or its related term are showing as below:
RSLBF'
s Days Payable Range Over the Past 10 Years
Min: 112.79 Med: 156.86 Max: 248.56
Current: 112.79
During the past 13 years, RaySearch Laboratories AB's highest Days Payable was 248.56. The lowest was 112.79. And the median was 156.86.
RSLBF's Days Payable is ranked better than 72.98% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58
vs RSLBF: 112.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, RaySearch Laboratories AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Days Payable distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Days Payable falls into.
RaySearch Laboratories AB Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RaySearch Laboratories AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (RSLBF) has a Days Payable of 121.14 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RaySearch Laboratories AB and its competitors. This is 23% below median its historical median of 156.86. Over the past decade, RaySearch Laboratories AB's Days Payable has ranged from 112.79 to 248.56. According to the industry distribution chart, RaySearch Laboratories AB ranks #164 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 27%.
Is RaySearch Laboratories AB's Days Payable too high?
RaySearch Laboratories AB's current Days Payable of 121.14 is 23% below median its 10-year median of 156.86. Over the past 10 years, this metric has ranged from a low of 112.79 to a high of 248.56. The Healthcare Providers & Services industry median Days Payable is 58.00. RaySearch Laboratories AB's value of 121.14 is 108.9% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #164 out of 607 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #164 out of 607 companies for Days Payable. This puts RaySearch Laboratories AB in the upper half of its industry. The industry median Days Payable is 58.00. RaySearch Laboratories AB's value of 121.14 is 108.9% above this benchmark. Historically, RaySearch Laboratories AB's own Days Payable has ranged from 112.79 to 248.56 over the past decade. While the company's 10-year median is 156.86 vs. the industry median of 58.00, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.00, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Days Payable of 121.14 is 108.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Days Payable is 121.14, which is 23% below median its own 10-year median of 156.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Fairly Valued. The stock's GF Value™ is $20.80, compared to a current price of $21.17 — trading 1.8% above its estimated fair value. The current Days Payable is 121.14, which is 23% below median its 10-year median of 156.86 and 108.9% above the Healthcare Providers & Services industry median of 58.00. RaySearch Laboratories AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current Days Payable is 121.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of $21.17 is trading 1.8% above its estimated GF Value™ of $20.80.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for RSLBF:
Days Payable: 121.14 (23% below median its 10-year median of 156.86)
GF Value™: $20.80 vs. price of $21.17 (1.8% above fair value)
Industry Position: 108.9% above the Healthcare Providers & Services median (#164 of 607)
No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
92GF Score
Get the complete analysis for RSLBF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSLBF has been successfully added to your 
